| Aug 19 |
CRISPR (CRSP) Loses 24% YTD: How Should You Play the Stock?
|
| Aug 14 |
Crispr's Casgevy Launch: Promising Start, Uncertain Future
|
| Aug 11 |
Got the Market Sell-Off Blues? Do These 3 Things Right Now
|
| Aug 9 |
3 Gene Editing Stocks with Potential to Transform Medicine
|
| Aug 8 |
Jim Cramer: This Energy Stock Is A Buy, Stay Away From DexCom
|
| Aug 8 |
7 Biotech Stocks to Buy for Their Game-Changing Potential
|
| Aug 7 |
Crispr Therapeutics Q2 Earnings: Casgevy Updates Underline 'Blockbuster' Potential
|
| Aug 7 |
The 3 Best Gene Editing Stocks to Buy in August 2024
|
| Aug 6 |
CRISPR Therapeutics (CRSP) Q2 Loss Wider Than Expected
|
| Aug 5 |
CRISPR Therapeutics files for secondary mixed shelf offering
|
